PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34175955-7	2021	Naive T-cells from HLA-A*02:01 positive and negative donors were activated with vancomycin; however the strength of the induced response was significantly stronger in donors expressing HLA-A*32:01.	Vancomycin	80-90	major histocompatibility complex, class I, A	Homo sapiens	19-24	
34175955-0	2021	Deciphering adverse drug reactions: in vitro priming and characterization of vancomycin-specific T-cells from healthy donors expressing HLA-A*32:01.	Vancomycin	77-87	major histocompatibility complex, class I, A	Homo sapiens	136-141	
34175955-2	2021	Vancomycin-induced DRESS is associated with the expression of HLA-A*32:01, suggesting that the drug interacts with this HLA to activate CD8+ T-cells.	Vancomycin	0-10	major histocompatibility complex, class I, A	Homo sapiens	62-67	
34175955-3	2021	The purpose of this study was to utilize PBMC from healthy donors to: (i) investigate whether expression of HLA-A*32:01 is critical for the priming naive of T-cells with vancomycin and (ii) generate T-cell clones (TCC) to determine whether vancomycin exclusively activates CD8+ T-cells and to define cellular phenotype, pathways of drug presentation and cross-reactivity.	Vancomycin	170-180	major histocompatibility complex, class I, A	Homo sapiens	108-113	
34175955-7	2021	Naive T-cells from HLA-A*02:01 positive and negative donors were activated with vancomycin; however the strength of the induced response was significantly stronger in donors expressing HLA-A*32:01.	Vancomycin	80-90	major histocompatibility complex, class I, A	Homo sapiens	185-190	
34175955-8	2021	Vancomycin-responsive CD4+ and CD8+ TCC from HLA-A*32:01+ donors expressed high levels of CXCR3 and CCR4, and secreted IFN-gamma, IL-13 and cytolytic molecules.	Vancomycin	0-10	major histocompatibility complex, class I, A	Homo sapiens	45-50	
34175955-11	2021	To conclude, this study provides evidence that vancomycin primes naive T-cells from healthy donors expressing HLA-A*32:01 through a direct pharmacological binding interaction.	Vancomycin	47-57	major histocompatibility complex, class I, A	Homo sapiens	110-115	
31158526-0	2019	A Rapid Allele-Specific Assay for HLA-A*32:01 to Identify Patients at Risk for Vancomycin-Induced Drug Reaction with Eosinophilia and Systemic Symptoms.	Vancomycin	79-89	major histocompatibility complex, class I, A	Homo sapiens	34-39	
35070271-8	2022	Vancomycin and dapsone use in HLA-A*32:01 and HLA-B*13:01 carriers, respectively, showed trends toward increased risk of type B ADRs.	Vancomycin	0-10	major histocompatibility complex, class I, A	Homo sapiens	30-35	
34039850-2	2021	RECENT FINDINGS: Recent HLA associations relevant to our understanding of immunopathogenesis and clinical practice include HLA-B*13:01 with co-trimoxazole-induced SCAR, and HLA-A*32:01 with vancomycin-DRESS, for which an extended HLA class II haplotype is implicated in glycopeptide antibiotic cross-reactivity.	Vancomycin	190-200	major histocompatibility complex, class I, A	Homo sapiens	173-178	
32439433-0	2021	Cross-reactivity between vancomycin, teicoplanin and telavancin in HLA-A*32:01 positive vancomycin DRESS patients sharing an HLA-Class II haplotype.	Vancomycin	25-35	major histocompatibility complex, class I, A	Homo sapiens	67-72	
32439433-0	2021	Cross-reactivity between vancomycin, teicoplanin and telavancin in HLA-A*32:01 positive vancomycin DRESS patients sharing an HLA-Class II haplotype.	Vancomycin	88-98	major histocompatibility complex, class I, A	Homo sapiens	67-72	
32439433-1	2021	CAPSULE SUMMARY: All fifteen patients with HLA-A*32:01 restricted vancomycin-induced DRESS, showed negative ex vivo responses to dalbavancin however two showed cross-reactivity to teicoplanin and telavancin.	Vancomycin	66-76	major histocompatibility complex, class I, A	Homo sapiens	43-48	
31158526-2	2019	The authors recently reported a strong association between HLA-A*32:01 and vancomycin-induced drug reaction with eosinophilia and systemic symptoms.	Vancomycin	75-85	major histocompatibility complex, class I, A	Homo sapiens	59-64	
31158526-9	2019	The assay demonstrates a sensitivity and specificity to differentiate the HLA-A*32:01 allele from closely related non-HLA-A*32 alleles and may be used in clinical settings to identify individuals with the risk allele before or during the course of vancomycin therapy.	Vancomycin	248-258	major histocompatibility complex, class I, A	Homo sapiens	74-79	
30776417-0	2019	HLA-A*32:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms.	Vancomycin	40-50	major histocompatibility complex, class I, A	Homo sapiens	0-5	
30776417-9	2019	Time-to-event analysis of DRESS development during vancomycin treatment among the HLA-A*32:01-positive group indicated that 19.2% had DRESS and did so within 4 weeks.	Vancomycin	51-61	major histocompatibility complex, class I, A	Homo sapiens	82-87	
30776417-10	2019	CONCLUSIONS: HLA-A*32:01 is strongly associated with vancomycin-induced DRESS in a population of predominantly European ancestry.	Vancomycin	53-63	major histocompatibility complex, class I, A	Homo sapiens	13-18	
30776417-11	2019	HLA-A*32:01 testing could improve antibiotic safety, help implicate vancomycin as the causal drug, and preserve future treatment options with coadministered antibiotics.	Vancomycin	68-78	major histocompatibility complex, class I, A	Homo sapiens	0-5